Compile Data Set for Download or QSAR
Report error Found 1749 of affinity data for UniProtKB/TrEMBL: P13569
LigandPNGBDBM160509(US9682969, 1 | US10280160, Example 1.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160510(US9682969, 2 | US10280160, Example 2.)
Affinity DataEC50:  1.50E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160511(US9682969, 3 | US10280160, Example 3.)
Affinity DataEC50:  1.50E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160512(US9682969, 6 | US9682969, 4 | US10280160, Example ...)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160513(US9682969, 5 | US10280160, Example 5.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160512(US9682969, 6 | US9682969, 4 | US10280160, Example ...)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160515(US9682969, 9 | US9682969, 7 | US10280160, Example ...)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160516(US9682969, 8 | US10280160, Example 8.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160515(US9682969, 9 | US9682969, 7 | US10280160, Example ...)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160518(US9682969, 10 | US10280160, Example 10.)
Affinity DataEC50:  1.50E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160519(US9682969, 11 | US10280160, Example 11.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160520(US9682969, 12 | US10280160, Example 12.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160521(US9682969, 13 | US10280160, Example 13.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160522(US9682969, 14 | US10280160, Example 14.)
Affinity DataEC50:  1.50E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160523(US9682969, 15 | US10280160, Example 15.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160524(US9682969, 16 | US10280160, Example 16.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160525(US9682969, 22 | US9682969, 17 | US10280160, Exampl...)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160526(US9682969, 18 | US10280160, Example 18.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160527(US9682969, 19 | US10280160, Example 19.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160528(US9682969, 25 | US9682969, 20 | US10280160, Exampl...)
Affinity DataEC50:  1.50E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160529(US9682969, 21 | US10280160, Example 21.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160525(US9682969, 22 | US9682969, 17 | US10280160, Exampl...)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160531(US9682969, 24 | US9682969, 23 | US10280160, Exampl...)
Affinity DataEC50:  1.50E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160531(US9682969, 24 | US9682969, 23 | US10280160, Exampl...)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160528(US9682969, 25 | US9682969, 20 | US10280160, Exampl...)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160534(US9682969, 26 | US10280160, Example 26.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160535(US9682969, 27 | US10280160, Example 27.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160536(US9682969, 28 | US10280160, Example 28.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160537(US9682969, 29 | US10280160, Example 29.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160545(US9682969, 30 | US10280160, Example 30.)
Affinity DataEC50:  1.50E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

LigandPNGBDBM160546(US9682969, 31 | US10280160, Example 31.)
Affinity DataEC50: <1.00E+4nMAssay Description:This protocol is designed to selectively screen small molecule compounds for F508del CFTR corrector activities in the YFP (yellow fluorescent protein...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281046(US10022352, Compound 307)
Affinity DataEC50:  981nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281047(US10022352, Compound 308)
Affinity DataEC50:  3.10E+3nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281048(US10022352, Compound 309)
Affinity DataEC50:  38.1nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281049(US10022352, Compound 318 | US10022352, Compound 31...)
Affinity DataEC50:  160nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281050(US10022352, Compound 311)
Affinity DataEC50:  81.8nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281051(US10022352, Compound 312)
Affinity DataEC50:  181nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281052(US10022352, Compound 313)
Affinity DataEC50:  284nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281053(US10022352, Compound 314)
Affinity DataEC50:  228nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281054(US10022352, Compound 315)
Affinity DataEC50:  272nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281055(US10022352, Compound 316)
Affinity DataEC50:  285nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281056(US10022352, Compound 317)
Affinity DataEC50:  4.53E+3nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281049(US10022352, Compound 318 | US10022352, Compound 31...)
Affinity DataEC50:  65.9nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281058(US10022352, Compound 319)
Affinity DataEC50:  39.1nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281059(US10022352, Compound 320)
Affinity DataEC50:  4.32E+3nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM281060(US10022352, Compound 321)
Affinity DataEC50:  1.81E+3nMAssay Description:Single-Channel Recordings activity of wt-CFTR and temperature-corrected ΔF508-CFTR expressed in NIH3T3 cells was observed using excised inside-o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM297396(US10117858, Example 2 | 3-Amino-6-bromo-5-trifluor...)
Affinity DataEC50:  15nMAssay Description:Fischer Rat Thyroid (FRT) epithelial cells, stably expressing human ΔF508-CFTR were used as monolayer cultures on permeable supports. Cl− ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM297397(US10117858, Example 9 | US10117858, Example 10 | U...)
Affinity DataEC50:  90nMAssay Description:Fischer Rat Thyroid (FRT) epithelial cells, stably expressing human ΔF508-CFTR were used as monolayer cultures on permeable supports. Cl− ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM297398(US10117858, Example 3 | 3-Amino-6-bromo-5-trifluor...)
Affinity DataEC50:  55nMAssay Description:Fischer Rat Thyroid (FRT) epithelial cells, stably expressing human ΔF508-CFTR were used as monolayer cultures on permeable supports. Cl− ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetCystic fibrosis transmembrane conductance regulator(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM297397(US10117858, Example 9 | US10117858, Example 10 | U...)
Affinity DataEC50:  112nMAssay Description:Fischer Rat Thyroid (FRT) epithelial cells, stably expressing human ΔF508-CFTR were used as monolayer cultures on permeable supports. Cl− ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1749 total ) | Next | Last >>
Jump to: